Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | DRD1 | P21728 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3697299 | 0.83 | SIGMAR1 (0.49) | SIGMAR1DRD1MAOAMAOBDRD2 | |
| SCHEMBL10465502 | 0.81 | SIGMAR1 (0.43) | SIGMAR1DRD1DRD5CYP3A4CYP2D6 | |
| SCHEMBL9797639 | 0.79 | SIGMAR1 (0.46) | SIGMAR1DRD1MAOAMAOBDRD2 | |
| Hydrochloric Acid SCHEMBL9797661 | 0.78 | SIGMAR1 (0.47) | SIGMAR1DRD1MAOAMAOBDRD2 | |
| SCHEMBL14461584 | 0.77 | IDO1 (0.59) | MAOAMAOBDRD2 | |
| SCHEMBL9797341 | 0.75 | DRD1 (0.49) | SIGMAR1DRD1DRD2DRD4DRD5 | |
| SCHEMBL9797385 | 0.75 | SIGMAR1 (0.43) | SIGMAR1DRD1MAOAMAOBDRD2 | |
| Bromide SCHEMBL9797412 | 0.74 | SIGMAR1 (0.42) | SIGMAR1DRD1MAOAMAOBDRD2 | |
| SCHEMBL9797504 | 0.74 | SLC6A2 (0.46) | SIGMAR1DRD1MAOAMAOBDRD2 | |
| Bromide SCHEMBL9797187 | 0.74 | DRD1 (0.48) | SIGMAR1DRD1DRD2DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560463-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7531557-B2 | Diaryl ethers as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | SIGMAR1 10/4885DRD1 144/4885MAOA 1146/4885 |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | SIGMAR1 10/4885DRD1 154/4885MAOA 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.